- Conditions
- Angelman Syndrome
- Interventions
- GTX-102, Sham-LP
- Drug · Procedure
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Location Directory
Clinical trials in Dallas, Texas
This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13791
Shown on this page
12
Current sort
Recently updated
Location scope
Dallas, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 601–612 of 13,791 matching trials in Dallas, TX.
Live ClinicalTrials.gov results.
Institutions in Dallas
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- LS301-IT 0.1 mg/kg
- Drug
- Lead sponsor
- Integro Theranostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- JNJ-81201887, Sham Procedure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 45
- States / cities
- Tucson, Arizona • Fullerton, California • La Jolla, California + 40 more
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer
- Interventions
- IM-1617
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 2 more
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 55
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
- Interventions
- ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
- Conditions
- Advanced HR+/HER2- Breast Cancer
- Interventions
- IEV407, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas
- Conditions
- Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
- Interventions
- Anti TNF therapy including infliximab, No Biologics
- Biological · Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 4,970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2038
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
- Conditions
- Cushing Syndrome
- Interventions
- relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 196
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Encinitas, California • Encino, California + 41 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 33
- States / cities
- San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more